• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

    2/2/23 6:16:05 AM ET
    $BNR
    Medical Specialities
    Health Care
    Get the next $BNR alert in real time by email
    SC 13G/A 1 d429745dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Burning Rock Biotech Limited

    (Name of Issuer)

    Class A Ordinary Shares, par value US$0.0002 per share

    (Titles of Class of Securities)

    G17173 108**

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **

    This CUSIP number applies to the Class A ordinary shares (“Class A Ordinary Shares”) of Burning Rock Biotech Limited (the “Issuer”). CUSIP number 12233L 107 applies to the American Depositary Shares (“ADSs”) of the Issuer, each ADS representing one Class A Ordinary Share.

     

     

     


    CUSIP No. G17173 108    13G    Page 2 of 9

     

      1    

      NAME OF REPORTING PERSONS

     

      Yusheng Han

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      People’s Republic of China

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      - 0 -

       6  

      SHARED VOTING POWER

     

      17,352,023

       7  

      SOLE DISPOSITIVE POWER

     

      - 0 -

       8  

      SHARED DISPOSITIVE POWER

     

      17,352,023

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      17,352,023

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      16.9%*

    12  

      TYPE OF REPORTING PERSON

     

      IN

     

    *

    Calculated based on the number in Row 9 above divided by all of the Issuer’s issued and outstanding Class A Ordinary Shares and Class B ordinary shares as a single class as of December 31, 2022.


    CUSIP No. G17173 108    13G    Page 3 of 9

     

      1    

      NAME OF REPORTING PERSONS

     

      Quantum Boundary Holdings Limited

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      - 0 -

       6  

      SHARED VOTING POWER

     

      17,352,023

       7  

      SOLE DISPOSITIVE POWER

     

      - 0 -

       8  

      SHARED DISPOSITIVE POWER

     

      17,352,023

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      17,352,023

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      16.9%*

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Calculated based on the number in Row 9 above divided by all of the Issuer’s issued and outstanding Class A Ordinary Shares and Class B ordinary shares as a single class as of December 31, 2022.


    Item 1(a).

    Name of Issuer:

    Burning Rock Biotech Limited

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    No. 5, Xingdao Ring Road North

    International Bio Island, Guangzhou, 510005

    People’s Republic of China

     

    Item 2(a).

    Name of Person Filing:

    Yusheng Han

    Quantum Boundary Holdings Limited

    (each, a “Reporting Person” and, collectively, “Reporting Persons”)

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    The principal business address of each of the Reporting Persons is as follows:

    c/o Burning Rock Biotech Limited

    No. 5, Xingdao Ring Road North

    International Bio Island, Guangzhou, 510005

    People’s Republic of China

     

    Item 2(c).

    Citizenship:

    Yusheng Han – People’s Republic of China

    Quantum Boundary Holdings Limited – British Virgin Islands

     

    Item 2(d).

    Titles of Classes of Securities:

    Class A Ordinary Shares, par value US$0.0002 per share

     

    Item 2(e).

    CUSIP Number:

    G17173 108*

     

      *

    This CUSIP number applies to the Class A Ordinary Shares of the Issuer. CUSIP number 12233L 107 applies to the ADSs of the Issuer, each ADS representing one Class A Ordinary Share.

     

    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):

     

                           (a)   ☐    Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).
      (b)   ☐    Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
      (c)   ☐    Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
      (d)   ☐    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    Page 4 of 9


                           (e)   ☐    Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
      (f)   ☐    Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
      (g)   ☐    Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
      (h)   ☐    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (13 U.S.C. 1813).
      (i)   ☐    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).
      (j)   ☐    Non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J).

     

      (k)   ☐    Group in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution:                        

     

    Page 5 of 9


    Item 4.

    Ownership

    The following information with respect to the beneficial ownership of the Issuer’s ordinary shares by each of the Reporting Persons is presented as of December 31, 2022:

     

    Reporting Person

       (a) Amount
    beneficially
    owned(1):
         (b)
    Percent
    of
    class(2):
        (c) Number of shares as to which
    the person has:
     
      (i) Sole
    power
    to vote
    or to
    direct
    the
    vote
         (ii) Shared
    power to
    vote or to
    direct the
    vote(1)
         (iii) Sole
    power to
    dispose or

    to direct the
    disposition
    of
         (iv) Shared
    power to
    dispose or
    direct the
    disposition
    of(1)
     

    Yusheng Han

         17,352,023        16.9 %      0        17,352,023        0        17,352,023  

    Quantum Boundary Holdings Limited

         17,352,023        16.9 %      0        17,352,023        0        17,352,023  

     

    (1)

    Includes (i) 27,175 Class A Ordinary Shares, and (ii) 17,324,848 Class A Ordinary Shares obtainable upon conversion of 17,324,848 Class B ordinary shares (“Class B Ordinary Shares”) of the Issuer. Quantum Boundary Holdings Limited, a company incorporated under the laws of the British Virgin Island, directly holds 27,175 Class A Ordinary Shares and 17,324,848 Class B Ordinary Shares. Quantum Boundary Holdings Limited is indirectly wholly owned and ultimately controlled by a family trust established under the laws of the Republic of Singapore and managed by J.P. Morgan Trust Company (Singapore) Pte. Ltd as the trustee. Mr. Yusheng Han is the settlor of the trust. Mr. Han and his family members are the beneficiaries of the trust. Mr. Han may thereby be deemed to beneficially own the 27,175 Class A Ordinary Shares and 17,324,848 Class B Ordinary Shares held by Quantum Boundary Holdings Limited. Class B Ordinary Shares of the Issuer are convertible, at the option of the holder, into Class A Ordinary Shares.

    (2)

    The percentage of the class of securities beneficially owned by each of the Reporting Persons as of December 31, 2022 is based on 102,643,444 outstanding ordinary shares of the Issuer as a single class, being the sum of 85,318,596 Class A Ordinary Shares and 17,324,848 Class B Ordinary Shares outstanding as of the same date, assuming conversion of all Class B Ordinary Shares into Class A Ordinary Shares, and excluding (i) the 473,404 Class A Ordinary Shares issued to the Issuer’s depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under the Issuer’s share incentive plans, and (ii) 3,023,138 Class A Ordinary Shares as treasury stock.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable.

     

    Page 6 of 9


    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certification.

    Not Applicable.

     

    Page 7 of 9


    Exhibit Index

     

    Exhibit No.   

    Description

    99.1    Joint Filing Agreement

     

    Page 8 of 9


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 2, 2023

     

    YUSHENG HAN
    By:   /s/ Yusheng Han

    Name:

     

    Yusheng Han

    QUANTUM BOUNDARY HOLDINGS LIMITED
    By:   /s/ Yusheng Han

    Name:

     

    Yusheng Han

    Title:

     

    Director

     

    Page 9 of 9

    Get the next $BNR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNR

    DatePrice TargetRatingAnalyst
    10/15/2021Outperform
    Cowen
    7/14/2021$39.94Outperform
    CICC
    More analyst ratings

    $BNR
    Financials

    Live finance-specific insights

    See more
    • Burning Rock Reports First Quarter 2024 Financial Results

      GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection an

      5/29/24 1:34:06 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024

      GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2024. Please register in advance of the conference using the link provided below and dial in 15 minutes prio

      5/23/24 2:00:00 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

      GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   Following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for our OverC™ Multi-Cancer Detection

      3/28/24 5:16:22 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Leadership Updates

    Live Leadership Updates

    See more
    • Burning Rock Announces Results of 2024 Annual General Meeting

      GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

      12/31/24 4:56:17 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024

      GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 31, 2024 at 10:00 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The AG

      12/3/24 6:45:12 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces Results of 2023 Annual General Meeting

      GUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2023 and to authorize the directors of the Company to determine the remuneration of the auditor;To re-elect Wendy Hayes,

      12/19/23 9:35:05 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Burning Rock Reports First Quarter 2025 Financial Results

      GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product, CanCatch® Custom supports advancement in oesophageal squamous cell carcinoma(OSCC)treatment, with results published in the Molecular Cancer in May 2025. The study is a two-arm, multicenter, randomized, doub

      6/6/25 3:31:54 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

      GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended December 31, 2024. 2024 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Dete

      3/25/25 7:45:42 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces Results of 2024 Annual General Meeting

      GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

      12/31/24 4:56:17 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen resumed coverage on Burning Rock Biotech

      Cowen resumed coverage of Burning Rock Biotech with a rating of Outperform

      10/15/21 7:18:12 AM ET
      $BNR
      Medical Specialities
      Health Care
    • CICC initiated coverage on Burning Rock Biotech with a new price target

      CICC initiated coverage of Burning Rock Biotech with a rating of Outperform and set a new price target of $39.94

      7/14/21 5:44:04 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Burning Rock Biotech Limited

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      11/14/24 12:29:09 PM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      2/14/24 4:05:59 PM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      2/14/24 12:45:51 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    SEC Filings

    See more
    • SEC Form 6-K filed by Burning Rock Biotech Limited

      6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

      6/6/25 6:07:22 AM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form 20-F filed by Burning Rock Biotech Limited

      20-F - Burning Rock Biotech Ltd (0001792267) (Filer)

      4/29/25 6:31:11 AM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Burning Rock Biotech Limited

      6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

      3/25/25 8:14:01 AM ET
      $BNR
      Medical Specialities
      Health Care